Welcome to our dedicated page for Alzamend Neuro news (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro stock.
Alzamend Neuro Inc (ALZN) is a clinical-stage biopharmaceutical company advancing novel treatments for neurodegenerative and psychiatric disorders. This news hub provides investors and researchers with essential updates on therapeutic developments, regulatory progress, and scientific breakthroughs.
Access timely announcements about ALZN's pipeline candidates: AL001 (ionic cocrystal lithium therapy) and AL002 (immunotherapeutic Alzheimer's vaccine). Track press releases covering clinical trial phases, partnership agreements, intellectual property developments, and financial disclosures.
Our curated news collection serves as a centralized resource for monitoring ALZN milestones in Alzheimer's research, bipolar disorder treatment innovations, and neurotherapeutic advancements. Bookmark this page for verified updates on FDA communications, peer-reviewed study publications, and strategic corporate decisions.
Alzamend Neuro announced the initial closing of a private placement, securing $500,000 from an investor. The total agreement allows for up to $25 million in preferred shares. Proceeds will fund clinical trials for treatments targeting Alzheimer's, bipolar disorder, major depressive disorder, and PTSD. The investor also received warrants for 800,000 shares of common stock, with potential for up to 20 million more if the full $25 million is invested. Additional funding milestones are tied to regulatory filings and partnership agreements. The initial funds include $311,356.16 from a converted term note. This financing supports ongoing clinical trials, including a Phase I/IIA trial of an Alzheimer's vaccine.
Alzamend Neuro, Inc. (ALZN) has entered into a Securities Purchase Agreement to sell $25 million of Preferred Shares in a registered direct offering and concurrent private placement. The Preferred Shares are convertible into Common Stock, have a 15% annual dividend, and come with Warrants to purchase up to 20 million shares of Common Stock. The proceeds will fund clinical trials and general working capital.
Alzamend Neuro, Inc. (ALZN) terminated its 'at-the-market' equity offering program to limit uncertainty and unfavorable dilution for its stockholders. The company had sold over 1 million shares and raised about $1.3 million. The termination will be effective on May 16, 2024, with no further sales planned under the program.
FAQ
What is the current stock price of Alzamend Neuro (ALZN)?
What is the market cap of Alzamend Neuro (ALZN)?
